Skip to main content

Retrospective Study

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Telix Pharmaceuticals
Telix PharmaceuticalsAustralia - Brisbane
1 program
18FN/A1 trial
Active Trials
NCT07238322Active Not Recruiting400Est. Feb 2026
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
ESView software with proscanN/A1 trial
Active Trials
NCT05308498Completed87Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Telix Pharmaceuticals18F
UNION therapeuticsESView software with proscan

Clinical Trials (2)

Total enrollment: 487 patients across 2 trials

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Start: Sep 2025Est. completion: Feb 2026400 patients
N/AActive Not Recruiting
NCT05308498UNION therapeuticsESView software with proscan

Retrospective Evaluation to Compare AKE-1 (Navicam SB) Capsule Endoscope System and PillCam SB3 Capsule System

Start: Mar 2022Est. completion: Apr 202287 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.